Akari Therapeutics (NQ: AKTX )

2.730 USD -0.070 (-2.50%)

Streaming Delayed Price Updated: 10:31 AM EST, Mar 8, 2021 Add to My Watchlist

Price and Volume

Volume	18,255
Open	2.770
Bid (Size)	2.700 (2)
Ask (Size)	2.750 (82)
Prev. Close	2.800
Today's Range	2.690 - 2.830
52wk Range	0.8700 - 4.210
Shares Outstanding	15,256,933
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Akari Therapeutics Announces a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) for Nomacopan in Trauma

March 04, 2021

Study of porcine model of blast injury and haemorrhagic shock underway with USAISR as part of the development of a clinical path for the use of nomacopan to treat trauma

Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis

February 25, 2021

Performance

YTD	+50.83%	+50.83%
1 Month	-3.19%	-3.19%
3 Month	+43.68%	+43.68%
6 Month	+72.78%	+72.78%
1 Year	+60.59%	+60.59%

More News

Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to treat Neuropathic Pain and Dermatological Disease

February 01, 2021

Akari Therapeutics to Participate in Two January Virtual Investor Conferences

January 06, 2021

Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress

December 11, 2020

Akari Therapeutics Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion Dependence in Patients with Paroxysmal Nocturnal

December 11, 2020

12 Health Care Stocks Moving In Friday's Pre-Market Session

March 05, 2021

Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal Disease

December 03, 2020

12 Health Care Stocks Moving In Thursday's After-Market Session

March 04, 2021

Akari Therapeutics' PASylated Nomacopan Shows Promising Action In Animal Studies

February 25, 2021

12 Health Care Stocks Moving In Monday's After-Market Session

February 22, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.